ROLE OF SLEEP DURATION IN CARDIOVASCULAR DISEASE

Sri Banerjee*, Ubong Usua. Walden University, Leola, USA

10.1136/bmjresp-2021-bssconf.50

Growing evidence suggests an association between both short and long duration of habitual sleep and adverse health outcomes. In order to determine whether the population longitudinal evidence supports the presence of a relationship between Chronic Kidney Disease (CKD) and cardiovascular disease (CVD)-mortality, and how sleep duration plays a role in mortality outcomes.

This is a population-based cohort study of National Health and Nutrition Examination Surveys participants between 2005 and 2010 with mortality data obtained through 2015. Adults aged 20 years or older with sleep duration information were included. CKD was defined as GFR<60 mL/min. Outcomes of CVD-mortality were evaluated using Cox regression.

The percentage of deaths from low sleep duration among the population (N=15,586) were higher among individuals without High School (HS) Diploma (12.8%) versus at least some college education (5.7%). The mean follow-up was 7.7 years. For CVD-mortality, the overall unadjusted hazard ratio (HR) of individuals with CKD to no CKD was 1.54 (95% confidence interval [CI], 1.11-2.14, p = 0.01). Adjusted HR was elevated, 1.59 (CI 1.01-2.52, p = .04), among those with excessive sleep duration but closer to 1.0 (0.62 CI 0.25-1.51, p < 0.25) among individuals with normal sleep duration, after controlling for medical (obesity, diabetes, and C-reactive protein) and demographic risk factors (age, gender, poverty-income-ratio, education, and ethnicity).

Our study shows an unambiguous and consistent pattern of increased risk of dying from cardiovascular disease among individuals with CKD. However, this relationship is especially pronounced among individuals who have excessive sleep duration, making it an important determinant of health. Screening for sleep disorders is especially important in the consideration of other chronic diseases like cardio renal syndrome.

REFERENCE

56 ROLE OF SLEEP DURATION IN CARDIOVASCULAR MORTALITY AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE

57 UK ADHERENCE RATES TO CONTINUOUS POSITIVE AIRWAY PRESSURE BEFORE AND AFTER THE START OF THE CORONAVIRUS PANDEMIC

1JuliaDielesen*, 2Peter Dickel, 3David R. Jones, 4A Siddiq Pulakal, 5Neil Ward, 6Justin C Pepperell, 7Simon Merritt, 8Joerg Steier, 9A Sathyapala. 1National Heart and Lung Institute, Imperial College London, London, UK; 2Harefield Hospital, Guy’s and St Thomas’s NHS Foundation Trust, Middlesex, UK; 3Wythenshawe Hospital, Manchester, UK; 4Derford Hospital, Plymouth, UK; 5Musgrove Park Hospital, Taunton, UK; 6Conquest Hospital, Hastings, UK; 7St. Thomas’s Hospital, Harefield Hospital, UK; 8King’s Health Partners, London, UK

Introduction The most efficacious treatment for obstructive sleep apnoea (OSA) is Continuous Positive Airway Pressure (CPAP). CPAP’s benefit is curtailed however, because many patients do not adhere to treatment, estimated from trials at 17-85%. Since the Covid-19 pandemic, US and French CPAP adherence rates have been reported to have changed. We sought to determine CPAP adherence rates of NHS patients pre-and post-pandemic.

Methods 5 sleep centres were recruited. To detect an 18% difference [US Philips Resperions survey% adherent 36% (2019) vs 18% (2020)], 80% power, p 0.05%, 2-tailed test, n =92. Average use at Night 3, 7, 14, 1 and 3 months and clinical data collected from 100 patients starting CPAP for first time in i) April 2019 and ii) September 2020, using Resmed Airview and clinical records. Adherence defined as CPAP use ≥4 hrs/night for ≥70% of nights, or at Night 3 median use ≥4 hrs.

Results See table 1 for patient characteristics. In 2019, in all centres,% of adherent patients fell from Night 3 to 3 months, with 3-month adherence rates between 29%-50% (p=0.025, figure 1). Similar was seen in 2020 in Conquest (CH) and Musgrove Park hospitals (MSH); in CH, higher% seen up to 1 month compared to 2019. In 2020, at Manchester (MH), Derford (DH) and Guy’s and St Thomas’s hospitals (GSTT) the% of adherent patients did not fall between Night 3 and 3 months; MH and DH maintained similar% to 2019, in GSTT, there was a smaller% starting at Night 3 compared to 2019 (30% vs 55%, p<0.0001). 2020 3-month adherence rates were different between centres (27-51%, p = 0.004).

Discussion 3 month adherence rates are low -at best 50%. Rates have changed at some centres since the pandemic, with change varying depending on the treatment pathway modifications implemented.